Evidence map›Paper›PMID 39889806›Full record

ReviewNanomedicine (London, England)2025

Bacteria-tumor symbiosis destructible novel nanocatalysis drug delivery systems for effective tumor therapy.

Jing Zang, Fang Yin, Ziyuan Liu, Fengqian Li, Yang Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jing ZangDepartment of Pharmacy, Shanghai Eighth People's Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China.
Fang YinNanomedicine and Intestinal Microecology Research Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China.
Ziyuan LiuNanomedicine and Intestinal Microecology Research Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China.
Fengqian LiDepartment of Pharmacy, Shanghai Eighth People's Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China.
Yang ZhangDepartment of Pharmacy, Shanghai Eighth People's Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is a significant threat to human health. The dynamic equilibrium between probiotics and pathogenic bacteria within the gut microbiota is crucial in mitigating the risk of CRC. An overgrowth of harmful microorganisms in the gastrointestinal tract can result in an excessive accumulation of bacterial toxins and carcinogenic metabolites, thereby disrupting the delicate balance of the microbiota. This disruption may lead to alterations in microbial composition, impairment of mucosal barrier function, potential promotion of abnormal cell proliferation, and ultimately contribute to the progression of CRC. Recently, research has indicated that intestinal presence of

Indexed as

Colorectal NeoplasmsDrug Delivery SystemsGastrointestinal MicrobiomeAnimalsAntineoplastic AgentsFusobacterium nucleatumHumansNanostructuresSymbiosisAntineoplastic Agentsantibacterial treatmentanti-tumor therapycolorectal cancerFusobacterium nucleatumnanomaterial

Identifiers

PMID39889806
PMCPMC11792809

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.